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OBJECTIVES: To determine the proportion of published cost-
minimization analyses (CMAs) that provided appropriate evi-
dence of equivalence between drug comparators. METHODS:
Medline, Embase, and International Pharmaceutical Abstracts
(from inception to December 2006) were searched using the
words “cost” and “minimization”. Included articles were those
that: claimed to be a CMA, compared costs between drugs,
reported original research, and were available as full-text
(abstracts/reviews/letters were not accepted). Data extraction
was performed by two independent reviewers and included: evi-
dence of equivalence, journal type, publication date, and class of
drug. To determine adequacy of evidence of equivalence, each
article was assessed for source of data as well as strength of effec-
tiveness between comparators, and categorized as: “adequate”,
“questionable”, and “inadequate”. All differences in raters’ deci-
sions were resolved through consensus. RESULTS: A total of 67
articles were assessed for evidence of equivalence. Of those, the
majority were from the US/Canada, followed by Europe. Only
one article was from outside these regions (Australia). CMAs
were most published in general medicine journals and in the ﬁeld
of cardiovascular drugs. Of the total accepted studies, 9 (13.4%)
were judged “adequate”, 21 studies (31.3%) were categorized as
“questionable”, and 37 (55.2%) studies had “inadequate” evi-
dence of equivalence of comparators. The majority of studies
failed to prove their comparators’ equivalence because the evi-
dence in the literature supported different outcome results,
because some of these studies simply assumed equivalence, or did
not provide any evidence at all. No correlation was found
between studies that provided “adequate” or “inadequate”
equivalence and year of publication. CONCLUSION: The
majority of studies failed to provide adequate evidence of the
suitability of CMA as an analytic technique. Guidelines should
be developed that explicitly specify criteria for the performance
of a CMA in future studies.
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ICER VS. IERC:THEORETICAL HEALTH ECONOMICS VS.
PRACTICAL DECISION MAKER BASED VALUE EVIDENCE
Walt JG
Allergan Inc, Irvine, CA, USA
OBJECTIVES: The incremental cost-effectiveness ratio (ICER) 
is commonly calculated by health-economic researchers as a
method to communicate the relative incremental value among
treatments. It is intended as evidence to determine whether a
drug is a good value. However, as a single number presented as
a value in a local currency it is poorly understood by the average
health care decision maker(s). The objective of this project was
to re-examine the ICER value and design an economic calcula-
tion that would be more readily understood and more easily
interpretable by the customers of health economic information,
the health care decision makers. METHODS: The components
of the ICER were evaluated and rearranged in various possible
calculations to yield a value that was comparable across differ-
ent treatments utilizing the available cost (price) and effec-
tiveness components of medical treatments. RESULTS: The
incremental effectiveness per incremental cost ratio (IECR) or
“incremental value” is proposed. The incremental difference in
effectiveness is expressed as a ratio to the incremental difference
in cost, with all factors expressed in percentages. We compared
the traditional ICER to the proposed IECR. If a new treatment
had an IECR value of 100% it would be considered neutral. If
the IECR was less than 100% it could be considered needing
alternative value, and any value greater than 100% would gen-
erally be considered positive value. Examples: Drug-A : Drug-B
Cost $100 : $160. Effectiveness 50% : 80%. ICER : IECR $200 :
100% = EVEN. Cost $100 : $140. Effectiveness 50% : 80%
ICER : IECR $133 150% = GOOD. Cost $100 : $180. Effective-
ness 50% : 80%. ICER : IECR $267 : 75% = POOR. CONCLU-
SION: The results of the IECR calculation are easily
interpretable and produce a value that is simple to compare
across treatments. The IECR removes The oretical value of the
ICER, which is difﬁcult for decision makers to interpret, and
replaces it with a value that has an interpretable reference range.
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OBJECTIVES: Budget Impact Analysis (BIA) addresses the ques-
tion of whether a new drug is affordable by the health care
system in which it is being introduced. In Canada, committees
and managers of each public drug plan make reimbursement
decisions regarding new drugs. Most drug plan managers now
require economic data, including a BIA, as part of the formal
decision process on the pricing and reimbursement of drugs.
There is currently no standardized method of performing and
presenting BIAs for submission. METHODS: A survey of repre-
sentatives across Canada and a review of 35 previously submit-
ted BIAs were conducted to assess existing needs for BIA
guidelines. Based on these ﬁndings, previously published guide-
lines (ISPOR) and input from the project’s Steering Committee,
BIA guidelines were developed to provide detailed instruction on
how BIAs should be performed. An interactive budget impact
model template was designed to facilitate BIA model develop-
ment. RESULTS: Five key problem areas were identiﬁed for
improvement in BIA models: Lack of transparency, inaccurate or
misapplied assumptions, generalized analysis non-speciﬁc or
inaccurate to jurisdiction and/or plan, inappropriate choice of
comparators; and overall quality. The guidelines and accompa-
nying template address these problems and cover model design,
analytic perspective, time horizon, target population, costing,
scenarios to be compared, uncertainty analysis, discounting and
validation methods that should be used when preparing a BIA
as well as provide detailed guidance on data inputs and data
sources. CONCLUSION: The BIA guidelines and accompanying
template address the requirements of each of the participating
drug plans in Canada. Both have been endorsed by the National
Prescription Drug Utilization Information System (NPDUIS)
Steering Committee and the PMPRB for the standardization of
BIA submissions. The intended audience includes those who
develop, submit or use BIA models, and drug plan managers who
evaluate BIA submissions.
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PROPOSAL FOR A METHODOLOGICAL CHANGE OF
PRACTISE: SEPARATING THE PROCESS OF ESTIMATING
CLINICAL EFFECTIVENESS FROM ECONOMIC EVALUATIONS
Waechter F, Müllner M
AGES PharmMed—the Austrian Medicines Agency, Wien, Austria
OBJECTIVES: Any economic evaluation of a health care inter-
vention is only as good as the effectiveness data it is built upon
(Drummond 1997). Despite this knowledge, the quality of infor-
mation on clinical effectiveness is still poor. METHODS: The
main reason is that most data, at least on medicinal drugs, is tai-
lored towards obtaining a market authorisation. Competent
authorities, in the European Union, the United States and
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Canada, are often granting market access on the basis of efﬁcacy
data alone. Because of this lack of effectiveness data, informa-
tion is mostly extrapolated from the existing efﬁcacy data. In
theory it should be left to evidence-based-medicine specialists to
estimate this information. In practise this is done as an integral
part of most economic evaluations. We challenge this practise
and propose to separate the estimation of effectiveness from the
overall process of economic evaluations. Our main argument is
that the estimation of effectiveness is not necessarily a core com-
petency for authors of economic evaluations. RESULTS: Hence
this crucial issue gets too little attention in discussions and guide-
lines of economic evaluations. Subsequently we argue that this
niche of evidence-based-medicine is still underdeveloped. It
urgently needs scientiﬁc discussion and development of its own
guidelines. CONCLUSIONS: We propose that the estimation of
effectiveness on the basis of efﬁcacy data should be done as an
endeavour in itself. This would make the appraisal of these two
distinct procedures, namely effectiveness assessment and eco-
nomic evaluation, clearer and thus more valuable. The European
Union is currently trying to develop this ﬁeld (Pharmaceutical
Forum Conclusions—Press release September 29, 2006).
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OBJECTIVES: To examine the role of two modes of adminis-
trations of surveys: mail and internet, and associated source of
biases on validation of results of patient surveys, set up by J
Winter and D McFadden at Berkeley. Since internet surveys are
increasing, especially for conjoint surveys in health care, it
becomes important to control such biases on estimators of
demand for care. Previous estimations of survey biases in con-
joint models for health care choices (e.g. Suzuki and Ohkusa on
common cold, 1999) did not address such sources of biases.
METHODS: Two experimental questionnaires designed in 2003
and 2004 were administered on AARP patients, with the two
modes of administration. This paper analyses responses to three
policy questions. They are measured with scaling responses,
similar to the one used for the validation stage of a new cost
index for physicians’ decision making. RESULTS: Results from
the 2003 survey show that there is systematic bias associated
with modes of administrations. The paper provides 2003 results
on three policy questions where scaling measures were used on
health care choices for different types of care; preliminary results
of a modiﬁed 2004 design of the 2005 survey will also be pro-
vided. Findings from Winter and McFadden suggest that there
are systematic biases between internet and mail surveys in the
range of 0.514 to 0.528 for the selected choice questions. These
results will be updated and discussed in the context of the cre-
ation of a sampled survey on primary care physicians combin-
ing mail and internet surveys CONCLUSION: This paper
contributes to methodological advances to improve validation of
new type of reversed conjoint surveys as predictive tools for
demand of health care, especially for the validation of physi-
cians’surveys, when there are a lot of variations in adoption of
IT systems in physicians’ practices.
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OBJECTIVES: Pharmacoeconomics (PE) has been deﬁned as ‘the
description and analysis of costs of drug therapy to health care
systems and society’. PE concepts and methods have been with
us since the early seventies. The trend in the use of PE in for-
mulary decision-making, disease management programmes and
cost-effectiveness of health care interventions is on the increase.
This study investigated the role of PE in decision-making in the
private and public sectors of the health care system in the
Gauteng region. METHODS: Two focus group sessions were
conducted at Technikon Pretoria. Face-to-face interviews were
also conducted with key informants in PE who did not partici-
pate in both focus groups. The triangulation method of com-
bining focus group methods and face-to face interviews was
chosen to increase the reliability of the data. Six and three par-
ticipants for the ﬁrst and second focus groups, respectively, with
similar backgrounds in PE were recruited from both the private
and public sectors. A moderator who was conversant in PE facil-
itated the focus group sessions while the researcher recorded the
responses from the participants. RESULTS: Using the Donabe-
dian matrix for the analysis, mixed results were observed in the
private and public sectors about the perception and use of PE.
There was an increased awareness of PE as a decision-making
tool by most respondents. Lack of PE culture, conﬂict of inter-
est, and wastage of resources were the most prevalent health care
concerns affecting both sectors of the health care system of the
Province. Although PE methods are globally transferable, models
are required to reﬂect the Gauteng Province’s health care setting.
CONCLUSION: PE exists as a decision-making tool aimed at
demonstrating the value for money in the allocation of health
care resources. PE is instrumental in understanding and solving
the health care issues faced by decision makers both sectors of
the health care system in the Gauteng Province.
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OBJECTIVES: To use item response theory (i.e. Rasch) analysis
to develop and evaluate scales to test prescribers’ DDI knowl-
edge and perceived usefulness of DDI information sources, and
to examine factors that may be associated with prescribers’ DDI
knowledge. METHODS: Data were obtained from a US national
mail survey sent to 12,500 prescribers. The survey instrument
included 14 drug-drug pairs that tested prescribers’ ability to rec-
ognize clinically important DDIs and ﬁve 5-point Likert scale-
type questions that assessed prescribers’ perceived usefulness of
DDI information provided by various sources. The knowledge
and usefulness questions were examined via Rasch dichotomous
and rating scale models, respectively. Regression analysis was
used to examine factors related to prescribers’ DDI knowledge
scores which were derived from Rasch analysis. RESULTS: None
hundred ﬁfty completed questionnaires were received. Rasch
analysis of knowledge and usefulness items revealed satisfactory
model-data ﬁt (inﬁt mean square  1.5 and outﬁt mean square
